Subscribe
artisteer
artisteer / iStockphoto.com
27 October 2017Americas

MSD antibiotic patent obvious, says Federal Circuit

Merck Sharp & Dohme (MSD) has suffered a loss at the US Court of Appeals for the Federal Circuit, after the court affirmed an earlier finding of obviousness.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
MSD fails in SCOTUS bid to revive record $2.5bn verdict
21 January 2021   A subsidiary of MSD has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Big Pharma
MSD fails in SCOTUS bid to revive record $2.5bn verdict
21 January 2021   A subsidiary of MSD has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated.

More on this story

Big Pharma
MSD fails in SCOTUS bid to revive record $2.5bn verdict
21 January 2021   A subsidiary of MSD has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team